AVTX · Avalo Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $59.0K | $441.0K | $1.92M | $18.05M | $5.40M | $6.70M |
| Cost of Revenue | - | - | $1.28M | $3.43M | $1.49M | $300.2K |
| Gross Profit | - | - | $640.0K | $14.62M | $3.91M | $6.40M |
| R&D | $50.08M | $24.44M | $13.78M | $31.31M | $59.84M | $32.19M |
| SG&A | $22.90M | $17.24M | $20.71M | $20.71M | $21.83M | $17.42M |
| Total Operating Expenses | $72.98M | $68.95M | $29.27M | $55.49M | $87.53M | $79.54M |
| D&A | $344.0K | $169.0K | $158.0K | $166.0K | $1.66M | $1.84M |
| Operating Income | ($72.92M) | ($68.51M) | ($27.35M) | ($37.44M) | ($82.13M) | ($72.84M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $165.0K | $114.0K | $14.0K | $28.0K | ($196.0K) | ($2.79M) |
| Net Income | ($78.26M) | ($35.13M) | ($31.54M) | ($41.66M) | ($84.38M) | ($63.50M) |
| EPS - Basic | ($5.84) | ($7.94) | ($114.00) | ($1063.20) | - | - |
| EPS - Diluted | ($5.84) | ($20.91) | ($114.00) | ($1063.20) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.86M | $134.55M | $7.42M | $13.17M | $54.59M | $18.92M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | $0 | $20.0K | $38.0K | $3.1K |
| Accounts Payable | $137.0K | $283.0K | $446.0K | $2.88M | $3.37M | $2.57M |
| Current Assets | $105.29M | $138.89M | $8.39M | $16.42M | $61.84M | $26.01M |
| Total Assets | $116.46M | $150.73M | $20.99M | $33.37M | $80.21M | $43.76M |
| Current Liabilities | $12.94M | $6.96M | $4.62M | $22.11M | $19.89M | $15.22M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $33.41M | $17.70M | $13.69M | $44.28M | $57.13M | $19.19M |
| Stockholders' Equity | $83.05M | $133.03M | $7.30M | ($10.91M) | $23.08M | $24.56M |
| Retained Earnings | ($448.52M) | ($370.26M) | ($335.13M) | ($303.82M) | ($262.17M) | ($177.79M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($51.46M) | ($49.06M) | ($30.68M) | ($26.75M) | ($70.89M) | ($40.54M) |
| Investing Cash Flow | ($81.72M) | $356.0K | ($133.0K) | ($95.0K) | ($113.0K) | $11.13M |
| Financing Cash Flow | $14.59M | $175.85M | $25.04M | ($14.70M) | $106.76M | $44.78M |
| CapEx | - | - | - | $95.0K | $113.0K | $62.7K |
| Free Cash Flow | - | - | - | ($26.85M) | ($71.00M) | ($40.60M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 33.3% | 81.0% | 72.4% | 95.5% |
| Operating margin | -123601.7% | -15535.6% | -1421.6% | -207.4% | -1521.6% | -1087.4% |
| EBITDA margin | -123018.6% | -15497.3% | -1413.4% | -206.5% | -1490.9% | -1059.9% |
| Net margin | -132642.4% | -7965.8% | -1639.5% | -230.8% | -1563.1% | -948.0% |
| Free cash flow margin | - | - | - | -148.7% | -1315.4% | -606.1% |
| FCF / Net income | - | - | - | 0.64 | 0.84 | 0.64 |
| R&D / Revenue | 84888.1% | 5541.3% | 716.4% | 173.4% | 1108.5% | 480.6% |
| SG&A / Revenue | 38813.6% | 3909.5% | 1076.5% | 114.7% | 404.4% | 260.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -67.2% | -23.3% | -150.3% | -124.8% | -105.2% | -145.1% |
| Return on equity | -94.2% | -26.4% | -431.9% | 381.7% | -365.5% | -258.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 | 1.71 |
| Quick ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 | 1.71 |
| Cash ratio | 1.23 | 19.33 | 1.61 | 0.60 | 2.74 | 1.24 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.40 | 1.13 | 2.87 | -3.06 | 3.48 | 1.78 |
| Liabilities / Assets | 0.29 | 0.12 | 0.65 | 1.33 | 0.71 | 0.44 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.09 | 0.54 | 0.07 | 0.15 |
| Inventory turnover | - | - | - | 171.70 | 39.24 | 95.73 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | 0d | 2d | 9d | 4d |
| Days payable outstanding | - | - | 127d | 306d | 825d | 3129d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 2.9x | 0.4x | 0.3x | - | - | - |
| P / S | 4126.0x | 126.3x | 1.3x | 630.5x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -86.6% | -77.1% | -89.3% | 234.4% | -19.4% | -0.8% |
| Revenue CAGR (3y) | -85.2% | -56.6% | -34.0% | 38.8% | -42.1% | 79.8% |
| Revenue CAGR (5y) | -61.2% | -42.1% | -41.4% | 73.4% | - | - |
| Gross profit growth (YoY) | - | - | -95.6% | 274.1% | -38.9% | -12.6% |
| Operating income growth (YoY) | -6.4% | -150.5% | 26.9% | 54.4% | -12.8% | -351.4% |
| Net income growth (YoY) | -122.8% | -11.4% | 24.3% | 50.6% | -32.9% | -295.1% |
| EPS growth (YoY) | 72.1% | 81.7% | 89.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 62.2% | -74.9% | -109.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -37.6% | 1721.4% | - | - | -6.0% | 17.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$59.0K totalProduct$59.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-3.59
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Avalo Therapeutics against the 5 most active filers in the same SIC group.